Nucana reports first quarter 2023 financial results and provides business update

Multiple important data readouts remain on track for 2023 well capitalized with anticipated cash runway into 2025 edinburgh, united kingdom, may 17, 2023 (globe newswire) -- nucana plc (nasdaq: ncna) announced financial results for the first quarter ended march 31, 2023 and provided an update on its broad clinical development program with its transformative protide therapeutics. as of march 31, 2023, nucana had cash and cash equivalents of £31.0 million compared to £41.9 million at december 31, 2022.
NCNA Ratings Summary
NCNA Quant Ranking